RESEARCH ARTICLE


Effect of Inhaled Corticosteroids on Glycemic Status



Francis Egbuonu 1, Farrah A Antonio 1, Mahamood Edavalath*, 2
1 Department of Medicine, University Hospital of North Staffordshire, ST4 6QG, UK
2 Department of Endocrinology & Diabetes, University Hospital of North Staffordshire, ST4 6QG, UK


Article Metrics

CrossRef Citations:
24
Total Statistics:

Full-Text HTML Views: 5824
Abstract HTML Views: 1866
PDF Downloads: 810
Total Views/Downloads: 8500
Unique Statistics:

Full-Text HTML Views: 2493
Abstract HTML Views: 1038
PDF Downloads: 559
Total Views/Downloads: 4090



Creative Commons License
© Egbuonu et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Endocrinology, Royal Stoke University Hospital, Stoke-on-Trent, ST4 6QG, UK; E-mail: edmahamood@hotmail.com


Abstract

Although the dysglycemic effects of systemic glucocorticoid therapy are well known, the effect of inhaled corticosteroids (ICS) on carbohydrate metabolism is still a subject of debate. The systemic bioavailability of ICS is claimed to be minimal and the side effects negligible. However, some large retrospective cohort studies showed a definite association between ICS use and incident diabetes or worsening glycemic control in pre-existing diabetes. There are no professional-body recommended guidelines on the diagnosis and management of steroid-induced diabetes for the general population. This review aims to evaluate the systemic dysglycemic effect of ICS treatment and to propose a management algorithm.

Keywords: Diabetes control, diabetes mellitus, dysglycemic status, hyperglycemia, inhaled corticosteroids (ICS), steroid-induced diabetes..